CARLSBAD, Calif., July 31, 2019 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced today the limited commercial launch of the Mariner Outrigger Revision System.
Mariner Outrigger is an implant system providing surgeons a high level of versatility for multiple revision applications. As an adjunct to the Mariner Posterior Fixation system, Mariner Outrigger includes a variety of options to effectively revise and extend previous fusions. The System offers a comprehensive implant and instrument offering, including several differentiated implant technologies, in a single tray that reduces the overall volume of product required to support complex cases.
“Through the launch of the Mariner Outrigger Revision System, SeaSpine is expanding the applications of its modular Mariner platform to address more complex cases,” stated Dennis Cirino, Senior Vice President, Global Spinal Systems. “This demonstrates our continued commitment to deliver world-class surgical solutions to our surgeon customers in the growing revision market.”
“Mariner Outrigger is designed to deliver versatility and simplicity in revision spine and deformity surgery,” stated Dr. Daryl Sybert, orthopedic surgeon at Mount Carmel, New Albany, OH. “It improves operative efficiency through streamlined instrumentation and implants in a reduced number of trays. Combined with the strength and versatility of Mariner, I have a high level of confidence when addressing my revision surgeries.”
The launch of the Mariner Outrigger Revision System is one of several complementary systems that will expand the applications of the Mariner Posterior Fixation System. SeaSpine expects to commercialize additional application-specific systems that expand the procedural application of its modular Mariner platform, including the planned launch of a minimally invasive system before the end of the third quarter of 2019.
SeaSpine (www.seaspine.com) is a global medical technology company focused on the design, development and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. SeaSpine has a comprehensive portfolio of orthobiologics and spinal implants solutions to meet the varying combinations of products that neurosurgeons and orthopedic spine surgeons need to perform fusion procedures on the lumbar, thoracic and cervical spine. SeaSpine’s orthobiologics products consist of a broad range of advanced and traditional bone graft substitutes that are designed to improve bone fusion rates following a wide range of orthopedic surgeries, including spine, hip, and extremities procedures. SeaSpine’s spinal implants portfolio consists of an extensive line of products to facilitate spinal fusion in degenerative, minimally invasive surgery (MIS), and complex spinal deformity procedures. Expertise in both orthobiologic sciences and spinal implants product development allows SeaSpine to offer its surgeon customers a differentiated portfolio and a complete solution to meet their fusion requirements. SeaSpine currently markets its products in the United States and in approximately 30 countries worldwide through a committed network of increasingly exclusive distribution partners.
SeaSpine cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that are based on the Company’s current expectations and assumptions. Such forward-looking statements include, but are not limited to, statements relating to: the design of the Mariner Outrigger Revision System, including to provide a high level of versatility, to revise and extend fusions, and to reduce the overall volume of product required to support complex cases; and the commercial availability of additional application-specific systems that will expand the procedural application of its modular Mariner platform, including the planned launch of a minimally invasive system before the end of the third quarter of 2019. Among the factors that could cause or contribute to material differences between the Company’s actual results and the expectations indicated by the forward-looking statements are risks and uncertainties that include, but are not limited to: the ability of newly launched products to perform as designed and intended and to meet the needs of surgeons and patients, including as a result of the lack of clinical validation of products in limited commercial (or “alpha”) launch; unexpected delay, including as a result of developing and supporting the launch of new products, including the fact that newly launched products may require substantial additional development activities, which could introduce further delay, or as a result of obtaining regulatory clearances; and other risks and uncertainties more fully described in the Company’s news releases and periodic filings with the Securities and Exchange Commission. The Company’s public filings with the Securities and Exchange Commission are available at www.sec.gov.
You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date when made. SeaSpine does not intend to revise or update any forward-looking statement set forth in this news release to reflect events or circumstances arising after the date hereof, except as may be required by law.
Investor Relations Contact
Source: SeaSpine Holdings Corporation